期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

结直肠恶性肿瘤的新标志物—肿瘤型丙酮酸激酶 被引量：5

Tumor type M2 pyruvate kinase-the new tumor marker in colorectal cancer
下载PDF
导出
摘要 肿瘤型丙酮酸激酶是近年来发现的一种新型肿瘤标志物,在消化道肿瘤早期诊断、疗效监测等方面的应用价值已得到证实。本文就其在结直肠癌的早期筛查、动态监测等方面的临床应用价值做一综述。 Tumor type M2 pyruvate kinase was recovered in recent years as a new tumor marker, which value in early diagnosis and therapeutic monitoring of gastrointestinal cancer has been confirmed. This article reviews the value of TU M2 - PK in ealy screening and monitoring of colorectal cancer.
作者 叶维洁 金冶宁
机构地区 上海交通大学医学院附属瑞金医院肿瘤放化疗科
出处 《现代肿瘤医学》 CAS 2009年第10期2018-2020,共3页 Journal of Modern Oncology
关键词 肿瘤型丙酮酸激酶 结直肠癌 肿瘤标志物 tumor M2 pyruvate kinase colorectal cancer tumor marker
分类号 R730.3 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Prakin DM. Global cancer statistics in year 2000 [ J ]. Lancet Oncol,2001,2:533 - 543.
  • 2Hardt PD, Ngoumou BK, Rupp J, et al. Tumor M2 - pyruvate kinase : a promising tumor marker in the diagnosis of gastro - intestinal cancer[ J ]. Anticancer Res,2000 ,20 :4965 - 4968.
  • 3厉明,梅同华.肺癌新标志——肿瘤M2型丙酮酸激酶[J].国际检验医学杂志,2006,27(5):446-447. 被引量：9
  • 4左强,罗荣城.M_2-PK的检测及其对恶性肿瘤的诊断价值[J].广东医学,2004,25(1):94-96. 被引量：6
  • 5Lftner D,Mesterharm J,Akrivakis C ,et al. Tumor type M2 pyruvate kinase expression in advanced breast cancer[ J]. Anticancer Res, 2000,20(6D) :5077 - 5082.
  • 6Oremek GM, Gerstmeier F, Sauer - Eppel H, et al. Pre - analytical problems in the measurement of tumor type pyruvate kinase (tumor M2 - PK) [ J]. Anticancer Res ,2003,23 (2A) : 1127 - 1130.
  • 7Ewald N, Schaller M, Bayer M, et al. Fecal pyruvate kinase - M2 ( tumor M2 - PK) measurement:a new screening concept for colorectal cancer[ J ]. Anticancer Res,2007,27 (4A) : 1949 - 1952.
  • 8BoZhang,Jian-YingChen,Dao-DaChen,Guo-BinWang,PingShen.Tumor type M_2 pyruvate kinase expression in gastric cancer,colorectal cancer and controls[J].World Journal of Gastroenterology,2004,10(11):1643-1646. 被引量：22
  • 9Shastri YM, Naumann M, Oremek GM, et al. Prospective multicenter evaluation of fecal tumor pyravate kinase type M2 ( M2 - PK) as a screening biomarker for colorectal neoplasia[ J]. lnt J Cancer,2006,119(11) :2651 -2656.
  • 10Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention[ J ]. Colorectal Dis ,2008,10 (3) :244 - 248.

二级参考文献35

  • 1Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D.Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.Anticancer Res 2000; 20:5095-5098.
  • 2Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, Jung K,Schnorr D, Loening SA. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003; 26.
  • 3Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loenng SA. Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients. Urology A 2000; 39:554-556.
  • 4Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA,CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.Anticancer Res 2000; 20:5053-5058.
  • 5Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G,Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22(1A): 311-318.
  • 6Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.Anticancer Res 2003: 23(2A): 899-906.
  • 7Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG,Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Clin Exp Med 2003;2:185-191.
  • 8Pottek T, Muller M, Blum T, Hartmann M. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 2000; 20:5029-5033.
  • 9Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE,Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20:5077-5082.
  • 10Hoopmann M, Warm M, Mallmann P, Thomas A, Gohring UJ,Schondorf T. Tumor M2 pyruvate kinase-determination in breast cancer patients receiving trastuzumab therapy. Cancer Lett 2002; 187:223-228.

共引文献27

同被引文献1638

引证文献5

二级引证文献9

现代肿瘤医学
2009年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部